In polycystic kidney disease (PKD), eGFR can decline as growing kidney cysts damage or crowd out healthy filtering tissue. The change is often gradual, but the pace differs widely, and one lower result does not prove that the disease is progressing faster. Clinicians look at repeated blood tests, blood pressure, urine tests, imaging, medicines, and recent illness to understand the pattern and choose next steps.
A falling estimated glomerular filtration rate (eGFR) is an important sign to review in someone living with PKD. It can indicate that the kidneys are filtering waste less effectively than before. Understanding whether the change represents a long-term decline or a temporary problem helps healthcare professionals decide what monitoring or treatment may be appropriate.
What does a declining eGFR mean in polycystic kidney disease?
eGFR estimates how well the kidneys filter waste and extra fluid from the blood. It is usually calculated from a blood creatinine result, along with factors used in the estimating equation. Some situations may call for additional information, such as a cystatin C blood test, to improve the estimate.
In PKD, fluid-filled cysts develop and enlarge within the kidneys. As the disease progresses, these changes can affect the healthy tissue responsible for filtering blood. Kidney function may gradually decrease as more of that tissue is affected, although the rate of change varies considerably between individuals. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) explains that the progression of autosomal dominant polycystic kidney disease (ADPKD) differs from person to person and is influenced in part by the gene involved.
A declining eGFR does not show exactly how many cysts are present or explain the cause of a change on its own. It is one part of the overall assessment of kidney health. The direction and pace of change over time are generally more informative than a single result.
Why can kidney function fall even when PKD causes few symptoms?
PKD can develop over many years, and a person may have few noticeable symptoms while kidney changes continue. The kidneys have a substantial capacity to maintain their filtering function, so changes in kidney structure and changes in eGFR do not always occur at the same pace.
For people with ADPKD, the underlying genetic pattern can also influence how quickly kidney function changes. For example, NIDDK notes that people with changes in the PKD1 gene generally progress to kidney failure faster than those with changes in the PKD2 gene. However, a person's genetic background is only one part of the clinical picture, and it does not determine an exact timeline for an individual.
Polycystic kidney disease includes more than one inherited condition. ADPKD commonly becomes apparent in adulthood, whereas autosomal recessive polycystic kidney disease (ARPKD) often presents during infancy or childhood. Kidney monitoring and treatment decisions need to reflect the specific type of PKD and the person's age.
Does one lower eGFR result mean PKD is getting worse?
Not necessarily. A lower result deserves attention, but it may reflect a temporary change rather than a lasting loss of kidney function. Creatinine levels can change for reasons other than long-term kidney damage, and the estimated value may be affected by illness, medication use, changes in hydration, or differences in muscle mass.
The National Kidney Foundation (NKF) explains that eGFR is an estimate rather than a direct measurement of kidney filtering capacity. Because factors other than kidney disease can influence the estimate, healthcare professionals interpret it alongside previous results and other clinical information.
When eGFR falls unexpectedly, a healthcare professional may consider whether a temporary illness or another kidney problem contributed to the change. Possible explanations include:
- Dehydration: Reduced fluid intake, vomiting, or diarrhea may contribute to an acute change in kidney function.
- Infection: A urinary tract or kidney infection may affect kidney function and needs appropriate assessment.
- Kidney stones or urinary blockage: These problems may interfere with normal urine flow.
- Medication effects: Some medicines can affect kidney function, particularly during illness or dehydration.
- Progression of PKD: Gradual loss of filtering function can occur as the underlying disease progresses.
These possibilities cannot be distinguished from an eGFR result alone. The timing of the change, recent symptoms, medication history, blood pressure, urine findings, and repeat blood tests help determine the most likely explanation.
How do doctors assess the rate of eGFR decline?
Healthcare professionals usually compare a series of creatinine and eGFR results rather than relying on one measurement. They may review results from several months or years to understand whether kidney function has remained relatively stable, decreased gradually, or changed more abruptly. The length of time needed to establish a meaningful pattern depends on the clinical situation.
The NIDDK guidance on eGFR estimates emphasizes that trends over time are often more useful for assessing changes in kidney function than a single estimated value. An eGFR trend can help clinicians understand progression, but results still need to be considered in the context of other medical findings.
Depending on the situation, an assessment may include:
- Repeat blood tests: These help confirm whether a change persists and whether creatinine is returning toward previous levels.
- Urine testing: Urine albumin and other findings can provide additional information about kidney health.
- Blood pressure measurements: High blood pressure can contribute to further kidney damage and is an important part of PKD care.
- Kidney imaging: Ultrasound or other imaging may show kidney size and cyst burden. In selected people with ADPKD, kidney volume measurements help clinicians estimate the risk of faster progression.
- Medication and health review: Recent illness, other medical conditions, and medicines that may affect kidney function are considered.
For people with ADPKD, the rate of eGFR decline can help guide decisions about treatment aimed at slowing progression. The 2025 clinical practice guideline from Kidney Disease: Improving Global Outcomes (KDIGO) includes recommendations for assessing progression risk and selecting treatment based on an individual's clinical circumstances.
What can help slow eGFR decline in PKD?
Although there is currently no cure that removes the inherited cause of PKD, appropriate management may help preserve kidney function and reduce additional damage. The most suitable approach depends on the type of PKD, the current level and trend of kidney function, blood pressure, other health conditions, and the person's treatment goals.
Keep blood pressure under control
High blood pressure is common in PKD and can place additional strain on the kidneys. Regular blood pressure checks and appropriate treatment are important parts of long-term care. A healthcare professional may recommend lifestyle changes or prescribe medication, including an angiotensin-converting enzyme inhibitor (ACE inhibitor) or an angiotensin receptor blocker (ARB), when appropriate.
The NIDDK guide to polycystic kidney disease describes blood pressure management as one way to help limit kidney damage associated with PKD. Treatment targets should be individualized, particularly when kidney function is changing or other medical conditions are present.
Review medicines and protect against additional kidney injury
Some medicines can affect kidney function or increase the risk of acute kidney injury. People with PKD should discuss pain relievers, nonprescription medicines, supplements, and changes to prescribed treatment with their healthcare professional. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, can be harmful to the kidneys in some circumstances, especially with repeated use or dehydration. Do not stop prescribed medicines without medical guidance.
Discuss fluid intake, diet, and daily habits
Regular physical activity, not smoking, and a balanced eating pattern can support overall health and help with blood pressure management. Limiting excess sodium may also be recommended. Fluid advice should be personalized rather than based on a universal daily target, because a person's needs can differ according to kidney function, other health conditions, and medicines.
People taking tolvaptan need particular guidance about fluid intake because the medicine increases urine production. Their healthcare team can explain how to manage thirst and fluid losses safely.
Ask whether tolvaptan is appropriate
Tolvaptan is a prescription medicine that may slow the rate of kidney function loss in selected adults with ADPKD who are at risk of rapid progression. It is not necessary or suitable for everyone with PKD, and it does not cure the condition or restore kidney tissue that has already been lost.
Decisions about tolvaptan depend on evidence of disease progression, kidney function, possible benefits, side effects, and the person's preferences. The medicine can cause substantial increases in urination and thirst, and it requires regular liver-function monitoring. A kidney specialist can explain whether the potential benefits outweigh the risks in a particular situation. Treatment considerations differ for children, who need care suited to their age and specific diagnosis.
When should a falling eGFR be reviewed promptly?
A new or unexpected eGFR decline should be brought to the attention of the healthcare professional managing the kidney condition. Contact the care team promptly if the change is substantial, develops over a short period, or occurs after a new medicine, infection, or illness that affects fluid intake. A sudden drop should not automatically be assumed to be the usual long-term progression of PKD.
Prompt medical assessment is particularly important when a change in kidney function occurs with fever and urinary symptoms, severe pain in the side or back, persistent vomiting, visible blood in the urine, or a marked reduction in urine output. These experiences can occur with complications that need separate evaluation. The Mayo Clinic's information on polycystic kidney disease describes complications such as kidney infections, stones, pain, and loss of kidney function that may require medical attention.
What does a continuing eGFR decline mean for the future?
A persistent decline can indicate that kidney function is being lost over time, but the rate of decline matters. Some people with PKD maintain useful kidney function for many years, while others experience faster progression. Current results, previous trends, imaging findings, blood pressure, and other health factors help clinicians estimate future risk and plan care.
If kidney function continues to decrease, a nephrologist may adjust monitoring and treatment or discuss planning for advanced kidney disease. When kidney failure eventually prevents the kidneys from adequately meeting the body's needs, dialysis or a kidney transplant may be considered. A falling eGFR alone does not mean that these treatments are needed soon; decisions are based on the overall clinical picture.
For anyone living with PKD, the practical goal is to understand the pattern of kidney function, address treatable factors that may contribute to a decline, and consider suitable options to slow progression. Keeping a record of previous results and bringing questions about changes to appointments can help make discussions with the healthcare team more useful.